Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

14

Revenue 2017

Lilly

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Lilly's 2013 sales performance.

Lilly

AZ’s Farxiga gets heart failure prevention okay from FDA

AZ’s Farxiga gets heart failure prevention okay from FDA It’s also an important win for AZ as it tries to chase down SGLT2 inhibitor market leader Jardiance (empagliflozin) from Eli Lilly and Boehringer Ingelheim. ... Boehringer and Lilly are testing Jardiance in both HFrEF and HFpEF with two trials –

Novartis grows in Q3 thanks to stellar performance of key drugs

Novartis grows in Q3 thanks to stellar performance of key drugs Novartis has also been facing increasing competition in this therapy area, from the likes of Eli Lilly/Boehringer Ingelheim’s Jardiance and AstraZeneca’s Farxiga.

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial Lilly has reported top-line results from the trial which show that pegilodecakin wasn’t able to improve overall survival (OS) over FOLFOX given alone. ... The pegylated formulation of interleukin-10 was the main asset in Lilly’s $1.6bn all-cash

Eli Lilly shutters UK neuroscience unit, with 80 job losses expected

Eli Lilly shutters UK neuroscience unit, with 80 job losses expected There will be no change to Lilly’s commercial infrastructure in Basingstoke, it says. ... Tim Garnett, Lilly’s chief medical officer, said the proposal “will be difficult news for many working for Lilly in the UK”.

Novartis’ Cosentyx scores again in phase 3, strengthens approval claim

Novartis’ Cosentyx scores again in phase 3, strengthens approval claim Novartis may have been first-to-market with Cosentyx, but it is still facing increasing competition, namely from Eli Lilly’s Taltz (ixekizumab). The rival IL-17 inhibitor won approval in

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics